サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1451722

免疫療法薬市場レポート：薬剤タイプ、治療領域、エンドユーザー、地域別、2024-2032

Immunotherapy Drugs Market Report by Drug Type, Therapy Area, End User, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 146 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.41円
免疫療法薬市場レポート：薬剤タイプ、治療領域、エンドユーザー、地域別、2024-2032
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 146 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の免疫療法薬の市場規模は2023年に2,130億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて7.75%の成長率（CAGR）を示し、2032年までに4,255億米ドルに達すると予測しています。高齢化に伴うさまざまな種類のがんの有病率の増加、個別化医療に対する需要の高まり、早期発見・早期治療に対する個人の意識の高まりなどが、市場を牽引する主な要因となっています。

免疫療法薬は、病気と闘ったりコントロールしたりするために免疫系を利用したり変更したりするように設計された医療治療法です。特定の細胞やタンパク質に作用し、健康な組織への害を最小限に抑えます。免疫療法薬は、他の治療法に比べて耐性ができにくく、治療成績が良く、副作用が少ないです。メラノーマ、肺がん、乳がんなど、さまざまながんの治療に利用されています。また、特定のアレルギー反応の管理や、関節リウマチ、ループス、多発性硬化症などの病気の治療にも使用されています。このほか、慢性炎症性疾患のコントロールにも有効であることから、免疫療法薬の需要は世界中で増加しています。

製薬業界の台頭と世界の薬局の拡大が、良好な市場見通しをもたらしています。さらに、バイオテクノロジー企業、製薬企業、研究機関の戦略的提携や合併・買収（M&A）が、免疫療法製品の研究開発・商業化活動を支えています。さらに、研究開発（R&D）活動における人工知能（AI）とビッグデータ解析の統合は、効率と精度を高めています。この技術統合により、標的の迅速な特定、臨床試験の最適化、患者の反応予測が可能となっています。

免疫療法薬の市場動向と促進要因：

対象疾患の増加

ライフスタイルの変化や不健康な食事パターンにより、さまざまな種類のがんの発生が増加しており、免疫療法のような革新的で効果的な治療法に対する需要が高まっています。さらに、早期発見と個別化治療の必要性が、患者やヘルスケアプロバイダーにこうした先進的な治療法の採用を促しています。これとは別に、急速な都市化や有害な自動車排気ガスによる汚染レベルの上昇が様々な慢性疾患の原因となっており、免疫療法治療の新たな機会を生み出しています。さらに、腫瘍やがん、その他の健康状態に罹患しやすい高齢化人口の増加が、免疫療法薬のような効果的な治療法や技術の必要性を高めています。

個別化医療の採用

より患者中心のアプローチを推進するため、様々な医療分野で個別化医薬品の利用が増加していることが、市場にプラスの影響を与えています。さらに、次世代シークエンシングやバイオマーカー分析などの高度な診断ツールの開発により、特定の免疫療法の対象となる患者を正確に特定できるようになっています。このような診断の進歩は、早期介入を容易にし、個別化された治療計画を可能にし、免疫療法の全体的な効果を高めるのに役立っています。これとは別に、個別化免疫療法は試行錯誤の可能性を減らします。さらに、このような的を絞ったアプローチにより、効果のない治療法の使用を最小限に抑え、不必要な副作用を回避し、早期回復を促し、ヘルスケアコストを削減することができるため、市場の成長に寄与しています。

政府と規制当局の支援

各国の政府・規制機関は、免疫療法薬や治療法の開発に継続的に注力しており、市場の見通しを良好なものにしています。また、新規免疫療法の開発や既存免疫療法の最適化に必要な綿密な研究を行うための財政支援も行われています。これとは別に、政府、研究機関、非公開会社のパートナーシップが市場の成長を支えています。このような協力関係は、知識の交換を促進し、国境を越えた画期的な免疫療法の開発を加速させています。さらに、政府によるヘルスケア政策の導入も、免疫療法の導入と償還を後押ししています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 免疫療法薬の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤タイプ別

  • モノクローナル抗体
    • 市場動向
    • 市場予測
  • ワクチン
    • 市場動向
    • 市場予測
  • インターフェロンα・β
    • 市場動向
    • 市場予測
  • インターロイキン
    • 市場動向
    • 市場予測

第7章 市場内訳：治療領域別

  • がん領域
    • 市場動向
    • 市場予測
  • 自己免疫疾患と炎症性疾患
    • 市場動向
    • 市場予測
  • 感染症
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • 診療所
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AstraZeneca plc
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG
    • GSK plc
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi S.A.
図表

List of Figures

  • Figure 1: Global: Immunotherapy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Immunotherapy Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Immunotherapy Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Immunotherapy Drugs Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Immunotherapy Drugs Market: Breakup by Therapy Area (in %), 2023
  • Figure 6: Global: Immunotherapy Drugs Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Immunotherapy Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Immunotherapy Drugs (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Immunotherapy Drugs (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Immunotherapy Drugs (Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Immunotherapy Drugs (Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Immunotherapy Drugs (Interferons Alpha and Beta) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Immunotherapy Drugs (Interferons Alpha and Beta) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Immunotherapy Drugs (Interleukins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Immunotherapy Drugs (Interleukins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Immunotherapy Drugs (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Immunotherapy Drugs (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Immunotherapy Drugs (Autoimmune and Inflammatory Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Immunotherapy Drugs (Autoimmune and Inflammatory Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Immunotherapy Drugs (Infectious Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Immunotherapy Drugs (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Immunotherapy Drugs (Other Therapy Areas) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Immunotherapy Drugs (Other Therapy Areas) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Immunotherapy Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Immunotherapy Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Immunotherapy Drugs (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Immunotherapy Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Immunotherapy Drugs (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Immunotherapy Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: North America: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: North America: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: United States: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: United States: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Canada: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Canada: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia-Pacific: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia-Pacific: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: China: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: China: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Japan: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Japan: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: India: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: India: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: South Korea: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: South Korea: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Australia: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Australia: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Indonesia: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Indonesia: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Europe: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Europe: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Germany: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Germany: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: France: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: France: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United Kingdom: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United Kingdom: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Italy: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Italy: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Spain: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Spain: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Russia: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Russia: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Latin America: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Latin America: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Brazil: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Brazil: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Mexico: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Mexico: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Middle East and Africa: Immunotherapy Drugs Market: Breakup by Country (in %), 2023
  • Figure 78: Middle East and Africa: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: Immunotherapy Drugs Industry: SWOT Analysis
  • Figure 80: Global: Immunotherapy Drugs Industry: Value Chain Analysis
  • Figure 81: Global: Immunotherapy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Immunotherapy Drugs Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Immunotherapy Drugs Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Immunotherapy Drugs Market Forecast: Breakup by Therapy Area (in Million US$), 2024-2032
  • Table 4: Global: Immunotherapy Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Immunotherapy Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Immunotherapy Drugs Market: Competitive Structure
  • Table 7: Global: Immunotherapy Drugs Market: Key Players
目次
Product Code: SR112024A6639

The global immunotherapy drugs market size reached US$ 213.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 425.5 Billion by 2032, exhibiting a growth rate (CAGR) of 7.75% during 2024-2032. The growing prevalence of different cancer types due to the aging population, rising demand for personalized medicines, and the increasing awareness among individuals about early detection and treatment are some of the major factors propelling the market.

Immunotherapy drugs are medical treatments designed to utilize or modify the immune system to fight or control diseases. They focus on specific cells and proteins and aid in minimizing harm to healthy tissues. They reduce the likelihood of developing resistance, offer better outcomes, and have fewer side effects as compared to other treatments. They are utilized in treating various types of cancers, including melanoma, lung, and breast cancer. They are also used in managing specific allergic reactions and treating diseases like rheumatoid arthritis, lupus, and multiple sclerosis. Besides this, as they are effective in controlling chronic inflammatory diseases, the demand for immunotherapy drugs is increasing across the globe.

The rise in the pharmaceutical industry and the expansion of pharmacies worldwide is offering a favorable market outlook. Moreover, strategic collaborations and mergers and acquisitions (M&A) between biotech firms, pharmaceutical companies, and research institutions are supporting the research, development, and commercialization activities of immunotherapy products. Furthermore, the integration of artificial intelligence (AI) and big data analytics in research and development (R&D) activities is enhancing efficiency and precision. This technological integration is enabling the rapid identification of targets, optimization of clinical trials, and prediction of patient responses.

Immunotherapy Drugs Market Trends/Drivers:

The increasing prevalence of target diseases

The rising occurrence of different types of cancer due to lifestyle changes and unhealthy dietary patterns is catalyzing the demand for innovative and effective treatments like immunotherapy is growing. Additionally, the early detection and need for personalized therapy options are encouraging patients and healthcare providers to adopt these advanced treatment alternatives. Apart from this, rapid urbanization and rising pollution levels due to harmful vehicular emissions are resulting in various chronic diseases, which is creating new opportunities for immunotherapy treatments. Furthermore, the increasing aging population, which is highly susceptible to tumor, cancer, and other health conditions, is driving the need for effective treatments and technologies, like immunotherapy drugs.

Adoption of personalized medicines

The increasing utilization of personalized medicines in various medical fields to promote a more patient-centered approach is positively influencing the market. Additionally, the development of advanced diagnostic tools, such as next-generation sequencing and biomarker analysis, is enabling the precise identification of patients for specific immunotherapies. These advancements in diagnostics facilitate early intervention and allow for personalized treatment plans, which aid in enhancing the overall effectiveness of immunotherapy. Apart from this, personalized immunotherapies reduce the likelihood of trial-and-error approaches. Furthermore, this targeted approach minimizes the use of ineffective treatments, avoids unnecessary side effects, facilitates quicker recoveries, and reduces healthcare costs, which is contributing to market growth.

Governmental and regulatory support

Governments and regulatory bodies of various countries are continuously focusing on the development of immunotherapy drugs and therapies, which is offering a favorable market outlook. Additionally, they are providing financial support for conducting the in-depth studies required to develop novel immunotherapies and optimize existing ones. Apart from this, partnerships between governments, research institutions, and private companies are supporting market growth. These collaborations facilitate knowledge exchange and accelerate the development of groundbreaking immunotherapy treatments across borders. Furthermore, the introduction of several supportive governmental healthcare policies is encouraging the adoption and reimbursement of immunotherapies.

Immunotherapy Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global immunotherapy drugs market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on drug type, therapy area and end user.

Breakup by Drug Type:

Monoclonal Antibodies

Vaccines

Interferons Alpha and Beta

Interleukins

Monoclonal antibodies represent the largest market segment

A detailed breakup and analysis of the market based on the drug type has also been provided in the report. This includes monoclonal antibodies, vaccines, interferons alpha and beta, and interleukins. According to the report, monoclonal antibodies accounted for the largest market share. These antibodies offer a highly specific and targeted approach. They are designed to attach distinct proteins and receptors on the surface of diseased cells, enabling precise intervention. Additionally, regulatory bodies support monoclonal antibody therapies, providing streamlined approval processes and encouraging rapid development and commercialization. Apart from this, ongoing research and investment into the development of monoclonal antibodies contribute to their dominant position in the market. Furthermore, increasing funding and collaboration within the scientific community continue to yield innovative solutions. Moreover, technological advancements in manufacturing processes are making the production of monoclonal antibodies more scalable and cost-effective.

Breakup by Therapy Area:

Cancer

Autoimmune and Inflammatory Diseases

Infectious Diseases

Others

Cancer accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the therapy area. This includes cancer, autoimmune and inflammatory diseases, infectious diseases, and others. According to the report, cancer represented the largest segment. The rising prevalence of cancer due to the aging population, lifestyle changes, and environmental factors represent one of the key factors positively influencing the market. Additionally, the growing awareness among individuals about the benefits of early diagnosis and treatment of cancer is catalyzing the demand for immunotherapy drugs. Immunotherapy offers targeted treatments that can identify and attack specific cancer cells, minimizing damage to healthy tissue, enhancing effectiveness, and reducing side effects. Apart from this, continuous investments from governmental bodies, private sectors, and philanthropic organizations are supporting cancer research, including the development of immunotherapies, which is offering a favorable market outlook. Furthermore, rising partnerships between pharmaceutical companies, research institutions, and healthcare providers are accelerating the development and accessibility of cancer immunotherapies.

Breakup by End User:

Hospitals

Clinics

Others

Hospitals hold the majority of the market share

A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals, clinics, and others. According to the report, hospitals hold the largest market share. Hospitals have a multidisciplinary team of specialists, including oncologists, immunologists, pharmacists, and nurses. These integrated teams enable a collaborative approach to patient care, ensuring the appropriate application and monitoring of immunotherapies. Additionally, they are equipped with state-of-the-art medical technologies and equipment. This access allows for the utilization of advanced immunotherapies. Apart from this, collaborations with pharmaceutical companies allow hospitals to gain early access to new immunotherapy drugs and technologies. These partnerships enhance the ability of hospitals to offer cutting-edge treatment options. Furthermore, they have established relationships with insurance providers and a better understanding of reimbursement policies. Moreover, many hospitals are involved in clinical trials and research collaborations, actively contributing to the advancement of immunotherapy.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest immunotherapy drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share as the region has a well-established healthcare infrastructure that allows for the efficient distribution and utilization of immunotherapy drugs. Sophisticated medical facilities and well-trained healthcare professionals facilitate the widespread adoption of these treatments. Additionally, the region witnesses substantial investments from public and private sectors in healthcare and biotechnology, which facilitates research, drug development, and commercialization of immunotherapy products. Apart from this, the regulatory bodies in North America, such as the Food and Drug Administration (FDA), offer a conducive environment for drug approval. Furthermore, strategic collaborations between academia, biotech firms, and pharmaceutical companies ensure a dynamic environment for continuous innovation and growth in the field of immunotherapy.

Competitive Landscape:

Companies are actively engaged in various activities to stay competitive and innovate. They are conducting extensive research and development (R&D) activities, working on discovering new targets and optimizing existing therapies. Additionally, these companies are forming strategic partnerships with academic institutions, leveraging their expertise to fuel innovation. Apart from this, they are investing in cutting-edge manufacturing technologies to produce immunotherapy drugs efficiently and at scale. Furthermore, regulatory teams within these companies are collaborating with governmental bodies to ensure compliance with emerging rules and gain expedited approvals for novel treatment. Moreover, many companies are actively participating in international conferences and symposia, sharing knowledge, and learning from global peers.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AstraZeneca plc

Bayer AG

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Company

F. Hoffmann-La Roche AG

GSK plc

Merck & Co. Inc.

Pfizer Inc.

Sanofi S.A.

Recent Developments:

In January 2022, Pfizer Inc. and BioNTech SE entered a strategic collaboration to develop an mRNA-based vaccine to prevent shingles.

In March 2023. Sanofi S.A. announced that it has received marketing authorization for Dupixent (dupilumab), the first biologic medicine for the treatment of moderate-to-severe atopic dermatitis in children.

In January 2021, Enara Bio and Boehringer Ingelheim International GmbH announced a strategic collaboration and licensing agreement for the research and development (R&D) of novel targeted cancer immunotherapy.

Key Questions Answered in This Report

  • 1. How big is the global immunotherapy drugs market?
  • 2. What is the expected growth rate of the global immunotherapy drugs market during 2024-2032?
  • 3. What are the key factors driving the global immunotherapy drugs market?
  • 4. What has been the impact of COVID-19 on the global immunotherapy drugs market?
  • 5. What is the breakup of the global immunotherapy drugs market based on the drug type?
  • 6. What is the breakup of the global immunotherapy drugs market based on the therapy area?
  • 7. What is the breakup of the global immunotherapy drugs market based on the end user?
  • 8. What are the key regions in the global immunotherapy drugs market?
  • 9. Who are the key players/companies in the global immunotherapy drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Immunotherapy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Interferons Alpha and Beta
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Interleukins
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Therapy Area

  • 7.1 Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Autoimmune and Inflammatory Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Infectious Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AstraZeneca plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Boehringer Ingelheim International GmbH
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GSK plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Merck & Co. Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.